Skip to content
Menu

Halozyme Therapeutics Says Disappointed That Higher Regional Court Overturned The Preliminary Injunction Ordering Merck To Refrain From Distributing And Offering Keytruda In Germany

Benzinga Newsdesk 4 hours ago

News

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to refrain from

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to refrain from distributing and offering Keytruda SC in Germany.

"We are disappointed that the Higher Regional Court overturned the preliminary injunction halting the launch of Keytruda SC in Germany. We disagree with the decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief, which is not precluded by today's decision," said Mark Snyder, Chief Legal Officer of Halozyme.

Separately and independently, in October 2026, a Dutch patent court prohibited Merck's European Marketing Approval holder from committing an infringement in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, by manufacturing or causing to be manufactured, offering, putting on the market or using Keytruda SC in those countries, or by importing it or holding it in stock for that purpose.

The patents at issue arise from Halozyme's extensive research into nearly 7,000 modifications to human hyaluronidases. Among their uses, these hyaluronidases pioneered by Halozyme provide a mechanism for the rapid SC administration of therapeutic drugs. Halozyme's comprehensive studies and innovations were a significant advancement to the field of human-derived hyaluronidases.

The MDASE™ patents are not included in Halozyme's ENHANZE® licensing program and are distinct from its ENHANZE® patents. Therefore, the outcome of the global enforcement of its MDASE™ patents against Merck will not impact ENHANZE®, the ability of any licensee to use ENHANZE®, or revenues Halozyme receives from ENHANZE® licensees.

Read at benzinga.com